Abstract
Abstract:Cancer antigen (CA)-125 is a useful tumor marker for the follow up of ovarian and lung cancer. It is a sensitive, but not specific, tumor marker. Increased serum CA-125 levels have already been described in a number of benign and malignant diseases. We report two cases of increased serum CA-125 levels status post thoracotomy for resection of an early stage lung tumor that regressed spontaneously 3 and 8 months following surgery. Serum CA-125 levels may increase after thoracotomy, unrelated to tumor recurrence. Therefore, CA-125 levels obtained postoperatively should be interpreted with caution.
This content is limited to qualifying members.
If you have an existing account please login now to access this article or view purchase options.
Create a free account, then purchase this article to download or access it online for 24 hours.
Create a free account, then purchase a subscription to get complete access to all articles for a full year.
References
References1. Kalantri Y, Naik G, Joshi SP, et al. Role of cancer antigen-125 from pleural & ascitis fluid samples in non malignant conditions. Indian J Med Res 2007;125:25–30.KalantriY]]NaikG]]JoshiSP&etal;Role of cancer antigen-125 from pleural & ascitis fluid samples in non malignant conditions.Indian J Med Res200712525-302. Gaspar M, Diez M, Rodriguez A, et al. Clinical value of CEA and CA-125 regarding relapsed and metastasis in resectable non-small cell lung cancer. Anticancer Res 2003;23:3427–3433.GasparM]]DiezM]]RodriguezA&etal;Clinical value of CEA and CA-125 regarding relapsed and metastasis in resectable non-small cell lung cancer.Anticancer Res2003233427-34333. Miralles C, Orea M, España P, et al. Cancer Antigen125 associated with multiple benign and malignant pathologies. Ann Surg Oncol 2003;10:150–154.MirallesC]]OreaM]]EspañaP&etal;Cancer Antigen125 associated with multiple benign and malignant pathologies.Ann Surg Oncol200310150-1544. Topalak O, Saygili U, Soyturk M, et al. Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study. Gynecol Oncol 2002;85:108–113.TopalakO]]SaygiliU]]SoyturkM&etal;Serum, pleural effusion, and ascites CA-125 levels in ovarian cancer and nonovarian benign and malignant diseases: a comparative study.Gynecol Oncol200285108-1135. Sari R, Camci C, Sevinc A, et al. The effect of abdominal surgery on serum CA-125 levels. Clin Exp Obstet Gynecol 2000;27:244–245.SariR]]CamciC]]SevincA&etal;The effect of abdominal surgery on serum CA-125 levels.Clin Exp Obstet Gynecol200027244-2456. Diez M, Torres A, Pollán M, et al. Prognostic significance of serum CA-125 antigen assay in patients with non-small cell lung cancer. Cancer 1994;73:1368–1376.DiezM]]TorresA]]PollánM&etal;Prognostic significance of serum CA-125 antigen assay in patients with non-small cell lung cancer.Cancer1994731368-13767. Hatzakis KD, Froudarakis ME, Bouros D, et al. Prognostic value of serum tumor markers in patients with lung cancer. Respiration 2002;69:25–29.HatzakisKD]]FroudarakisME]]BourosD&etal;Prognostic value of serum tumor markers in patients with lung cancer.Respiration20026925-29
